Uso de fármacos antidepresivos en el tratamiento del síndrome de intestino irritable.
Saved in:
| Title: | Uso de fármacos antidepresivos en el tratamiento del síndrome de intestino irritable. |
|---|---|
| Alternate Title: | Use of antidepressant drugs in the treatment of irritable bowel syndrome. |
| Authors: | Cedeño Cedeño, Maylin Michelle1 maylincede@gmail.com, Cedeño Moreira, Jeffry Freddy1, Camacho Díaz, María José2, Palma Chávez, Paola Elizabeth3, Moreira Marquinez, Silvia Patricia4, Falcones Espinoza, Andrea Michelle4, Bravo Véliz, Stephani Beatriz4, Moreira Alava, Rocke Alberto5, Ganchozo Mendoza, Adrián Alexander2 |
| Source: | Archivos Venezolanos de Farmacología y Terapéutica. 2019, Vol. 38 Issue 6, p809-813. 5p. |
| Subjects: | SEROTONIN uptake inhibitors, MENTAL health services, IRRITABLE colon, TRICYCLIC antidepressants, ANTIDEPRESSANTS, PSYCHOLOGICAL factors, VISCERAL pain |
| Abstract (English): | The irritable bowel syndrome (IBS) is a highly frequent functional gastrointestinal disorder. A large part of the decrease in quality of life and the increase in economic burden associated with IBS stems from its widely variable nature, the multiplicity of available treatments, and the heterogeneity of the clinical results upon them. Current IBS therapy contemplates modifications in diet and physical activity, mental health care, and pharmacotherapy. The latter includes, among others, the use of antispasmodics, probiotics, antibiotics, and antidepressants (AD), especially selective serotonin reuptake inhibitors and tricyclic antidepressants. These are a particularly attractive alternative, as they may simultaneously manage the disease's psychological and physiological factors, such as those directly related with neurotransmission and intestinal local signaling. Although the theoretical foundation is rich, available clinical experience has highlighted the nuances and limitations of their use in practice. In the future, further research is needed to elucidate the ideal mode of prescription, as well as the specific AD with better balance between benefits and adverse effects, and the real relationship between the symptoms of IBS proper and depressive-anxious symptoms. Clarification of these aspects would serve as an invaluable orientation for the development of individualized treatment plans for each patient with IBS. This review explores current basic and clinical pharmacological aspects concerning the use of AD in the treatment of IBS. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | El síndrome de intestino irritable (SII) es un trastorno funcional gastrointestinal altamente frecuente. Gran parte del decremento en la calidad de vida y el incremento de la carga económica asociados al SII se deben a la naturaleza ampliamente variable de la enfermedad, la multiplicidad de tratamientos disponibles y la heterogeneidad de los resultados clínicos ante estos tratamientos. La terapia actual del SII contempla modificaciones en la dieta y la actividad física, atención en salud mental, y farmacoterapia. A su vez, ésta incluye, entre otros, el uso de antiespasmódicos, probióticos, antibióticos y antidepresivos (AD), especialmente los inhibidores selectivos de la recaptura de serotonina y los antidepresivos tricíclicos. Éstos constituyen una alternativa particularmente atractiva, en tanto podría abordar de manera simultánea los factores psicológicos de la enfermedad, así como factores fisiológicos directos relacionados con la neurotransmisión y señalización tisular intestinal. Si bien el fundamento fisiológico hipotético es muy rico, la experiencia clínica disponible ha resaltado los matices y limitaciones de uso en la práctica. En el futuro, se requiere mayor investigación para dilucidar el modo de prescripción idóneo, así como los agentes AD específicos con el mejor equilibrio entre beneficios y efectos adversos, y la relación real entre la sintomatología propia del SII y la sintomatología depresiva-ansiosa. La clarificación de estos aspectos serviría como una orientación invaluable en la confección de planes terapéuticos individualizados para cada uno de los pacientes con SII. En esta revisión se exploran los aspectos farmacológicos básicos y clínicos concernientes al uso de AD en el tratamiento del SII. [ABSTRACT FROM AUTHOR] |
| Copyright of Archivos Venezolanos de Farmacología y Terapéutica is the property of Archivos Venezolanos de Farmacologia y Terapeutica and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 141763222 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Uso de fármacos antidepresivos en el tratamiento del síndrome de intestino irritable. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Use of antidepressant drugs in the treatment of irritable bowel syndrome. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Cedeño+Cedeño%2C+Maylin+Michelle%22">Cedeño Cedeño, Maylin Michelle</searchLink><relatesTo>1</relatesTo><i> maylincede@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Cedeño+Moreira%2C+Jeffry+Freddy%22">Cedeño Moreira, Jeffry Freddy</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Camacho+Díaz%2C+María+José%22">Camacho Díaz, María José</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Palma+Chávez%2C+Paola+Elizabeth%22">Palma Chávez, Paola Elizabeth</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Moreira+Marquinez%2C+Silvia+Patricia%22">Moreira Marquinez, Silvia Patricia</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Falcones+Espinoza%2C+Andrea+Michelle%22">Falcones Espinoza, Andrea Michelle</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Bravo+Véliz%2C+Stephani+Beatriz%22">Bravo Véliz, Stephani Beatriz</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Moreira+Alava%2C+Rocke+Alberto%22">Moreira Alava, Rocke Alberto</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Ganchozo+Mendoza%2C+Adrián+Alexander%22">Ganchozo Mendoza, Adrián Alexander</searchLink><relatesTo>2</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Archivos+Venezolanos+de+Farmacología+y+Terapéutica%22">Archivos Venezolanos de Farmacología y Terapéutica</searchLink>. 2019, Vol. 38 Issue 6, p809-813. 5p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22SEROTONIN+uptake+inhibitors%22">SEROTONIN uptake inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22MENTAL+health+services%22">MENTAL health services</searchLink><br /><searchLink fieldCode="DE" term="%22IRRITABLE+colon%22">IRRITABLE colon</searchLink><br /><searchLink fieldCode="DE" term="%22TRICYCLIC+antidepressants%22">TRICYCLIC antidepressants</searchLink><br /><searchLink fieldCode="DE" term="%22ANTIDEPRESSANTS%22">ANTIDEPRESSANTS</searchLink><br /><searchLink fieldCode="DE" term="%22PSYCHOLOGICAL+factors%22">PSYCHOLOGICAL factors</searchLink><br /><searchLink fieldCode="DE" term="%22VISCERAL+pain%22">VISCERAL pain</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: The irritable bowel syndrome (IBS) is a highly frequent functional gastrointestinal disorder. A large part of the decrease in quality of life and the increase in economic burden associated with IBS stems from its widely variable nature, the multiplicity of available treatments, and the heterogeneity of the clinical results upon them. Current IBS therapy contemplates modifications in diet and physical activity, mental health care, and pharmacotherapy. The latter includes, among others, the use of antispasmodics, probiotics, antibiotics, and antidepressants (AD), especially selective serotonin reuptake inhibitors and tricyclic antidepressants. These are a particularly attractive alternative, as they may simultaneously manage the disease's psychological and physiological factors, such as those directly related with neurotransmission and intestinal local signaling. Although the theoretical foundation is rich, available clinical experience has highlighted the nuances and limitations of their use in practice. In the future, further research is needed to elucidate the ideal mode of prescription, as well as the specific AD with better balance between benefits and adverse effects, and the real relationship between the symptoms of IBS proper and depressive-anxious symptoms. Clarification of these aspects would serve as an invaluable orientation for the development of individualized treatment plans for each patient with IBS. This review explores current basic and clinical pharmacological aspects concerning the use of AD in the treatment of IBS. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: El síndrome de intestino irritable (SII) es un trastorno funcional gastrointestinal altamente frecuente. Gran parte del decremento en la calidad de vida y el incremento de la carga económica asociados al SII se deben a la naturaleza ampliamente variable de la enfermedad, la multiplicidad de tratamientos disponibles y la heterogeneidad de los resultados clínicos ante estos tratamientos. La terapia actual del SII contempla modificaciones en la dieta y la actividad física, atención en salud mental, y farmacoterapia. A su vez, ésta incluye, entre otros, el uso de antiespasmódicos, probióticos, antibióticos y antidepresivos (AD), especialmente los inhibidores selectivos de la recaptura de serotonina y los antidepresivos tricíclicos. Éstos constituyen una alternativa particularmente atractiva, en tanto podría abordar de manera simultánea los factores psicológicos de la enfermedad, así como factores fisiológicos directos relacionados con la neurotransmisión y señalización tisular intestinal. Si bien el fundamento fisiológico hipotético es muy rico, la experiencia clínica disponible ha resaltado los matices y limitaciones de uso en la práctica. En el futuro, se requiere mayor investigación para dilucidar el modo de prescripción idóneo, así como los agentes AD específicos con el mejor equilibrio entre beneficios y efectos adversos, y la relación real entre la sintomatología propia del SII y la sintomatología depresiva-ansiosa. La clarificación de estos aspectos serviría como una orientación invaluable en la confección de planes terapéuticos individualizados para cada uno de los pacientes con SII. En esta revisión se exploran los aspectos farmacológicos básicos y clínicos concernientes al uso de AD en el tratamiento del SII. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Archivos Venezolanos de Farmacología y Terapéutica is the property of Archivos Venezolanos de Farmacologia y Terapeutica and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=141763222 |
| RecordInfo | BibRecord: BibEntity: Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 5 StartPage: 809 Subjects: – SubjectFull: SEROTONIN uptake inhibitors Type: general – SubjectFull: MENTAL health services Type: general – SubjectFull: IRRITABLE colon Type: general – SubjectFull: TRICYCLIC antidepressants Type: general – SubjectFull: ANTIDEPRESSANTS Type: general – SubjectFull: PSYCHOLOGICAL factors Type: general – SubjectFull: VISCERAL pain Type: general Titles: – TitleFull: Uso de fármacos antidepresivos en el tratamiento del síndrome de intestino irritable. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cedeño Cedeño, Maylin Michelle – PersonEntity: Name: NameFull: Cedeño Moreira, Jeffry Freddy – PersonEntity: Name: NameFull: Camacho Díaz, María José – PersonEntity: Name: NameFull: Palma Chávez, Paola Elizabeth – PersonEntity: Name: NameFull: Moreira Marquinez, Silvia Patricia – PersonEntity: Name: NameFull: Falcones Espinoza, Andrea Michelle – PersonEntity: Name: NameFull: Bravo Véliz, Stephani Beatriz – PersonEntity: Name: NameFull: Moreira Alava, Rocke Alberto – PersonEntity: Name: NameFull: Ganchozo Mendoza, Adrián Alexander IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2019 Type: published Y: 2019 Identifiers: – Type: issn-print Value: 07980264 Numbering: – Type: volume Value: 38 – Type: issue Value: 6 Titles: – TitleFull: Archivos Venezolanos de Farmacología y Terapéutica Type: main |
| ResultId | 1 |
